key: cord-0948279-ig0e67id
authors: Darrigade, Anne‐Sophie; Théophile, Hélène; Sanchez‐Pena, Paola; Milpied, Brigitte; Colbert, Marianne; Pedeboscq, Stéphane; Pistone, Thierry; Jullié, Marie‐Laure; Seneschal, Julien
title: Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine
date: 2021-07-03
journal: Allergy
DOI: 10.1111/all.14981
sha: c987968849ae4a752fe18bf8a27e5fe74eb2d430
doc_id: 948279
cord_uid: ig0e67id

nan

To the editor, A 45-year-old woman, without any past medical history or allergy presented in our clinic with a rapid onset of diffuse skin eruptions. Leukocytoclastic vasculitis could be present in SS. 7 One case of SS in a patient receiving pneumococcal vaccine showed the presence of dermal vasculitis associated with infiltration of neutrophils. 6 Most cases of cutaneous reaction under SARS-CoV-2 Pfizer-BioNTech mRNA vaccine do not constitute a contraindication to a second injection. 3 To our knowledge, any case of SS induced by vaccine was re-challenged with the same vaccine. To date, the second SARS-CoV-2 Pfizer-BioNtech mRNA vaccine injection was not performed because of patient's refusal.

To conclude, we report the first case of SS induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. 

European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions

Cutaneous reactions to vaccinations

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single centre case series

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Sweet's syndrome triggered by pneumococcal vaccination

Acute febrile neutrophilic dermatosis: a histopathologic study of 31 cases with review of literature

The authors acknowledge the Uppsala Monitoring Centre (UMC) which provided some data presented in the present study. Marie-Laure Jullié 6